Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESRIX-II for radiation-induced hyposalivation and xerostomia
2018-000348-24Phase 2Completed
- Sponsor
- Department of Otorhinolaryngology, Head and Neck Surgery
- Start
- Mar 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CSCC_ASC in xerostomia and hyposalivation (2 arms), sponsored by Department of Otorhinolaryngology, Head and Neck Surgery. Primary endpoint: Change in unstimulated salivary flow rate. Started Mar 2018; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
xerostomiahyposalivation
Beyond the preview
Go deeper on 2018-000348-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000348-24.